Skip to main content

Table 5 Longitudinal Outcomes in YMRS and HAM-D: monotherapy versus individual combination therapies

From: A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder

Predictors YMRS HAM-D
Estimates CI p Estimates CI p
Group [Li] 1.80 − 1.77–5.37 0.319 2.29 − 0.87–5.45 0.153
Group [QTP] − 0.83 − 4.36–2.69 0.640 0.66 − 2.46–3.78 0.675
Time [days] − 0.13 − 0.18 to − 0.08 < 0.001*** − 0.05 − 0.09 to − 0.02 0.004**
Site [VA] 0.41 − 3.31–4.13 0.826 − 4.60 − 8.14 to − 1.07 0.011*
Group [Li] × time − 0.06 − 0.14–0.01 0.108 − 0.00 − 0.06–0.05 0.878
Group [QTP] × time 0.00 − 0.06–0.07 0.919 0.04 − 0.01–0.09 0.124
  1. PBO: monotherapy divalproex plus placebo [reference group]; Li: combination therapy of divalproex plus blinded lithium; QTP: divalproex plus blinded quetiapine; VA: Palo Alto VA
  2. *p < 0.05, **p < 0.01, ***p < 0.001